Font Size:
a
A
A
Keyword [Nilotinib]
Result: 21 - 36 | Page: 2 of 2
21.
Mechanism Of The Sphingosine-1-phosphate Pathway With Related Inhibitors On The Malignant Biological Behaviors Of Pancreatic Cancer
22.
Observation Of Imatinib And Nilotinib In The Treatment Of Chronic Myeloid Leukemia
23.
Retrospective Clinical Study Of Nilotinib As A Second-line Therapy In Imatinib Treatment-failure Patients With Chronic Myeloid Leukemia In Chronic Phase
24.
The Curative Effect And Adverse Reactions Of The First-line Treatment Of CML-CP Were Observed In Nilotinib And Imatinib
25.
Study On The Molecular Pathogenesis And Targeted Therapy In Acute Myeloid Leukemia
26.
The Research On TKIs-related Adverse Events And Efficacy In Chronic Myeloid Leukemia
27.
Prognostic Value Of BCR-ABL And Clinical Significance Of ABL Kinase Domain Mutation After TKIs
28.
Efficacy Evaluation Of Nilotinib Treatment In Different Genomic Subtypes Of Gastrointestinal Stromal Tumors: A Meta-analysis
29.
The Relationship Between UGT1A1 Gene Polymorphism And Nilotinib-induced High Bilirubin And The Study Of TKI Treatment In Elderly CML Patients
30.
Nilotinib (TasignaRTM) Modulates ABCB1/PGP- and ABCG2/BCRP-mediated multidrug resistance in cancer chemotherapy
31.
Clinical Observation On The Treatment Of Nilotinib Together With Interferon-α In Chronic Myeloid Leukemia Patients With Warning Efficacy
32.
Feasibility Analysis Of Prioritizing Imatinib As First-line Treatment For Chronic Myeloid Leukemia In Chronic Phase
33.
Clinical Analysis Of Second-line Treatment Of Chronic Myeloid Leukemia With Nilotinib And Dasatinib
34.
Clinical Efficacy Observation Of First-line And Second-line Treatment With Nilotinib In Chronic Myeloid Leukemia
35.
The Efficacy And Mechanism Of Niltotinib As A Novel ILK Inhibitor In Esophageal Squamous Cell Carcinoma Based On Molecular Docking Technology
36.
A Comparative Study Of First-and Second-line Application Of Nilotinib In Patients With Chronic Myeloid Leukemia In The Chronic Phase
<<First
<Prev
Next>
Last>>
Jump to
